BofA Securities Reiterates Neutral Rating on Cytokinetics (CYTK)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. GPRK
6. SCHW
7. TRV
8. TFC
9. NVDA
10. POLYCAB:IN

Go back to BofA Securities Reiterates Neutral Rating on Cytokinetics (CYTK)

Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting

September 5, 2024 4:00 PM EDT

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two presentations at the 2024 American College of Clinical Pharmacology (ACCP) Annual Meeting in Bethesda, MD from September 8, 2024 September 10, 2024.

Title: A First-in-Human, Single & Multiple Ascending Dose Study of CK-4021586, A Novel Cardiac Myosin Inhibitor
Presenter: Justin Lutz, Pharm. D., Ph.D., Senior Director, Clinical Pharmacology, Cytokinetics
Date: September 8, 2024
Session Title: Opening Reception, Exhibits & Poster Session 1
Topic: Pharmacokinetics (Including PopPK, ADME,... More